Xencor reported Q4 earnings, missing EPS estimate by $0.67, with 81.94% negative net margin and 17.26% negative ROE.

Biopharmaceutical company Xencor (NASDAQ:XNCR) reported Q4 earnings, missing analysts' consensus estimate of $0.36 EPS by $0.67, with a negative net margin of 81.94% and a negative return on equity of 17.26%. Revenue was $44.70M, up 106.9% YoY, with a 12-month high of $32.59. Shares traded down $3.88 to $22.64 on midday Wednesday, having a market cap of $1.38B, a P/E ratio of -11.44, and a beta of 0.70.

February 28, 2024
5 Articles

Further Reading